Eloxx Pharmaceuticals, Inc.
ELOX
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.39M | 1.80M | 2.00M | 3.43M | 2.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.64M | 4.14M | 5.48M | 6.03M | 7.14M |
| Operating Income | -3.64M | -4.14M | -5.48M | -6.03M | -7.14M |
| Income Before Tax | -3.59M | -4.34M | -6.23M | -6.32M | -7.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.59M | -4.34M | -6.23M | -6.32M | -7.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.59M | -4.34M | -6.23M | -6.32M | -7.51M |
| EBIT | -3.64M | -4.14M | -5.48M | -6.03M | -7.14M |
| EBITDA | -3.62M | -4.13M | -5.47M | -6.02M | -7.12M |
| EPS Basic | -1.31 | -1.96 | -2.88 | -2.92 | -3.47 |
| Normalized Basic EPS | -0.88 | -1.23 | -1.68 | -1.82 | -2.17 |
| EPS Diluted | -1.31 | -1.96 | -2.88 | -2.92 | -3.47 |
| Normalized Diluted EPS | -0.88 | -1.23 | -1.68 | -1.82 | -2.17 |
| Average Basic Shares Outstanding | 2.75M | 2.21M | 2.17M | 2.17M | 2.17M |
| Average Diluted Shares Outstanding | 2.75M | 2.21M | 2.17M | 2.17M | 2.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
